GlassScriptPhysician profile
James W Roberts
NPI 1083657522
$8,600.16
in general payments reported to CMS, 2019-2025
30 companies · $1,306 in 2025
The $1,306 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,167 · 2020: $427 · 2021: $823 · 2022: $1,399 · 2023: $823 · 2024: $1,654 · 2025: $1,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,764 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,764.15 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,620.27 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $975.57 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $751.44 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $697.71 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $605.20 | 2019-2025 | Watchman Flx, Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $491.86 | 2019-2025 | Wainua, Farxiga, Andexxa |
| Heartflow, INC. | $421.78 | 2022-2025 | Ffrct |
| Pfizer INC. | $309.01 | 2019-2025 | |
| Abbott Laboratories | $282.15 | 2019-2023 | Mitraclip |
| E.R. Squibb & Sons, L.L.C. | $272.37 | 2019-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $253.51 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $240.41 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $193.86 | 2022 | |
| Amarin Pharma, INC. | $182.97 | 2019-2022 | |
| Daiichi Sankyo INC. | $130.43 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $129.32 | 2020-2025 | Lifevest |
| Esperion Therapeutics, INC. | $116.68 | 2023-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $115.26 | 2019 | |
| Scpharmaceuticals INC. | $104.88 | 2023-2025 | |
| Akcea Therapeutics, INC. | $103.12 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $92.37 | 2021-2023 | Arcalyst |
| Novo Nordisk INC | $85.93 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Medtronic Vascular, INC. | $84.24 | 2020 | |
| Irhythm Technologies, INC. | $83.51 | 2022-2023 | Zio Xt Patch |
| Cvrx, INC. | $61.59 | 2023-2024 | Barostim Neo System |
| Regeneron Healthcare Solutions, INC. | $50.60 | 2022-2024 | Evkeeza |
| Kiniksa Pharmaceuticals International, Plc | $47.00 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $40.26 | 2023-2025 | Assure Wcd |
| Mannkind Corporation | $33.81 | 2025 | |
| Livanova USA, INC. | $23.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.